Melidonia Health to serve as exclusive distributor in Cyprus of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) for the treatment of cluster headaches and migraines

By 25 January 2022 March 11th, 2022 News, Pharmaceutical, Press

electroCore Inc., a commercial stage bioelectronic medicine company, has announced that it has entered into agreements with Melidonia Health Services to serve as the exclusive distributor of the gammaCore SapphireTM non-invasive vagus nerve stimulator (nVNS) in Cyprus.

“Melidonia Health works to improve the availability of novel and state-of-the-art health care products that facilitate the role of physicians, and in doing so, improve the lives of their patients,” commented Ioannis Kouis, General Manager of Melidonia Health. “Melidonia Health is a partner of choice for pharmaceutical and other health care companies, and we are excited to add electroCore to our network. As experts within the neurological and cardiology fields, electroCore compliments Melidonia Health’s existing portfolio of products and expertise.”

The initial term of the Melidonia Health agreement is three years – the new agreement contains customary terms and conditions, and regulatory clearances are required before sales and revenue can occur.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology.

For more information, visit www.electrocore.com

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache. It uses mild electrical stimulation to the vagus nerve that passes through the skin.

When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers which may lead to a reduction of pains in patients.

Designed as a portable, easy-to-use technology, gammaCore can be self-administrated by patients, as needed, without the potential side effects associated with commonly prescribed drugs.

gammaCore (nVNS) is FDA approved in the United States for a series of indications associated with cluster headaches and migraines both in adults and adolescents. gammaCore (nVNS) is also CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache and Medication Overuse Headache in adults, as well as epilepsy, anxiety and depression, gastric motility disorders and reactive airways disease.

About Melidonia Health Services

Melidonia Health Services is a member of C.A.PAPAELLINAS Group, established in 2014 as a sales and marketing organisation.

Melidonia Health aims to improve the availability of novel and state of art health care products that facilitate the role of physicians and improve the patients’ life.

Melidonia Health’s product portfolio includes medical devices, pharmaceuticals, reagents, diagnostic services, all aiming to allow doctors to improve their clinical practice, to improve their diagnostic decision process making and to reduce the suffering of patients.

For more information, visit Melidonia Health Services™